Tenofovir Amibufenamide
Chronic Hepatitis B Liver Fibrosis
Ningbo No.2 HospitalSmall moleculePhase 1Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Chronic Hepatitis B Liver Fibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lamivudine Yonsei University | Phase 4 | BBB |
Entecavir Beijing Continent Pharmaceutical Co, Ltd. | Phase 4 | BBB |
TENOFOVIR DISOPROXIL FUMARATE Ningbo No.2 Hospital | Phase 4 | BBB |
Telbivudine The Fifth People's Hospital of Suzhou | Phase 4 | BBB |
Adefovir Dipivoxil Asian-Pacific Alliance of Liver Disease, Beijing | Phase 4 | BB |
View all 29 →
Same molecule, other indications
Tenofovir Amibufenamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →